| Dec'19 | Dec'18 | Dec'17 | Dec'16 | |||
|---|---|---|---|---|---|---|
Cash Flows from Operating Activities: | ||||||
Net loss | ||||||
-46,389 | -30,662 | -31,288 | -12,654 | |||
Issuance of common shares - Equity fee on At-the-Market Offering to Fortress Biotech | ||||||
495 | 0 | - | - | |||
Issuance of common shares - Equity fee on Public Offering to Fortress Biotech | ||||||
791 | 0 | - | - | |||
Issuance of common shares - Equity fee on Horizon Notes to Fortress Biotech | ||||||
375 | 0 | - | - | |||
Common shares issuable for Founders Agreement | ||||||
4,923 | 2,085 | - | - | |||
Research and development - licenses acquired | ||||||
1,350 | 1,275 | - | - | |||
Research and development - licenses acquired | ||||||
1,350 | 1,275 | - | - | |||
Change in fair value of derivative liabilities | ||||||
- | - | - | 159 | |||
Stock-based compensation expenses | ||||||
2,664 | 4,960 | 2,012 | 0 | |||
Depreciation expense | ||||||
1,300 | 600 | 2 | 0 | |||
Research and development - licenses acquired | ||||||
- | - | 2,875 | 0 | |||
Issuance of common shares - Founders Agreement | ||||||
- | - | 1,234 | 862 | |||
Common shares issuable for Founders Agreement | ||||||
- | - | 9,558 | 4,396 | |||
Accretion of debt discount | ||||||
710 | 0 | - | 763 | |||
Amortization of operating lease right-of-use assets | ||||||
110 | 0 | - | - | |||
Capital contribution from Fortress | ||||||
- | - | 2,062 | 0 | |||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Changes in operating assets and liabilities: | ||||||
Prepaid expenses and other current assets | ||||||
- | - | 278 | - | |||
Prepaid expenses and other current assets | ||||||
558 | 757 | - | - | |||
Prepaid expenses | ||||||
- | - | - | 0 | |||
Interest receivables | ||||||
0 | 35 | 106 | 0 | |||
Other receivables - related party | ||||||
19 | 0 | - | - | |||
Accounts payable and accrued expenses | ||||||
296 | 2,470 | - | - | |||
Accounts payable and accrued expenses | ||||||
- | - | 1,332 | 668 | |||
Payable and accrued expenses - related party | ||||||
360 | 99 | 12 | -250 | |||
Accrued interest - related party | ||||||
- | - | -413 | 245 | |||
Deferred rent | ||||||
0 | -691 | -50 | 0 | |||
Lease liabilities | ||||||
-53 | 0 | - | - | |||
Net cash used in operating activities | ||||||
-33,581 | -19,244 | -12,948 | -4,129 | |||
Purchase of short-term investment (certificates of deposit) | ||||||
0 | 52,500 | 46,002 | 0 | |||
Maturity of certificate of deposit | ||||||
17,604 | 61,002 | - | - | |||
Maturity of certificate of deposit | ||||||
- | - | 20,000 | 0 | |||
Purchase of research and development licenses | ||||||
1,350 | 1,075 | 2,375 | 0 | |||
Purchase of fixed assets | ||||||
2,345 | 6,870 | 424 | - | |||
Purchase of fixed assets - construction-in-process | ||||||
- | - | - | 0 | |||
Security deposits paid | ||||||
- | - | 251 | 0 | |||
Net cash provided by investing activities | ||||||
13,909 | 557 | -29,052 | 0 | |||
Cash Flows from Financing Activities: | ||||||
Proceeds from Horizon Notes | ||||||
15,000 | 0 | - | - | |||
Proceeds from Fortress Note | ||||||
- | - | - | 2,221 | |||
Payment of Fortress Note | ||||||
- | - | 320 | 2,001 | |||
Payment from NSC Note | ||||||
- | - | - | -3,600 | |||
Debt issuance costs | ||||||
1,393 | 0 | - | - | |||
Proceeds from Horizon Note, net of debt discount | ||||||
- | - | 50,296 | 35,008 | |||
Proceeds from exercise of warrants | ||||||
0 | 181 | 0 | - | |||
Proceeds from issuance of common shares - At-the-Market Offering | ||||||
22,515 | 0 | - | - | |||
Offering costs for the issuance of common shares - At-the-Market Offering | ||||||
543 | 0 | - | - | |||
Proceeds from issuance of common shares - Public Offering | ||||||
31,625 | 0 | - | - | |||
Offering costs for the issuance of common shares - Public Offering | ||||||
2,088 | 0 | - | - | |||
Net cash provided by financing activities | ||||||
65,116 | 181 | 49,976 | 31,628 | |||
Net change in cash, cash equivalents and restricted cash | ||||||
45,444 | -18,506 | - | - | |||
Net change in cash, cash equivalents and restricted cash | ||||||
- | - | 7,976 | 27,499 | |||
Supplemental disclosure of cash flow information: | ||||||
Cash paid for interest | ||||||
1,057 | 0 | 413 | 140 | |||
Supplemental disclosure of noncash investing and financing activities: | ||||||
Fixed assets (acquired but not paid) | ||||||
187 | 196 | 959 | - | |||
Construction-in-progress included in accounts payable and accrued expenses | ||||||
- | - | - | 0 | |||
Property, plant and equipment included in account payable and accrued liabilities | ||||||
- | - | - | 0 | |||
Issuance of common shares - Founders Agreement | ||||||
2,085 | 9,558 | 4,396 | 190 | |||
Research and development licenses included in accounts payable and accrued expenses | ||||||
0 | 200 | - | - | |||
Research and development licenses included in accounts payable and accrued expenses | ||||||
- | - | 500 | 0 | |||
Issuance of warrants - Horizon Notes | ||||||
888 | 0 | - | - | |||
Common shares issuable for license acquired | ||||||
- | - | - | 1,682 | |||
Warrant liability associated with NSC Note | ||||||
- | - | - | 793 | |||
Exchange of Class A Preferred stock and common stock | ||||||
- | - | - | 1 | |||
Transfer from Fortress of NSC Note, net of discount of $0, $129 and $0, respectively | ||||||
- | - | - | 3,471 | |||
Common shares issuable for license acquired | ||||||
- | - | 1,682 | 0 | |||